Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 2, 2011, Pages 487-490

  Li, Chengguang ^a   Huang, Xin En ^a   Li, Ying ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Irinotecan; Nedaplatin; Small cell lung cancer

Indexed keywords

EID: 79958798504     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ando Y, Saka H, Ando M, et al (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, 60, 6921-6.
2. Ariyoshi Y, Ota K, Wakui A, et al (1988). Phase I study of (glycolato-O,O')diammineplatinum(II) (254S). Proc Am Soc Clin Oncol, 7, 59
3. Beutler E, Gelbart E, Demina A (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promote; a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA, 95, 8170-4.
4. Evans WK, Shepherd FA, Feld R, et al (1985). VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol, 3, 1471-7.
5. Fukuda M, Shinkai T, Eguchi K, et al (1990). Phase II study of (glycolate-O,O')diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol, 26, 393.
6. Gehan EA, Tefft MC (2000). Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81.
7. Hanna NH, Einhorn L, Sandler A, et al (2005). Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated, extensive-stage small cell lung cancer. Proc ASCO, LBA 7004.
8. Hirose T, Horichi N, Ohmori T, et al (2003). Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer, 40, 333-8.
9. Ihde DC, Mulshine JL, Kramer BS, et al (1994). Prospective randomized comparison of high-does and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol, 12, 2022-34.
10. Kameyama Y, Okazaki N, Nakagawa M, et al (1990). Nephrotoxicity of a new platinum compound, 254S, evaluated with rat kidney cortical slices. Toxicol Lett, 52, 15.
11. Kanzawa F, Koizumi F, Koh Y,et al (2001). In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this action. Clin Cancer Res, 7, 202.
12. Lampe JW, Bigler J, Horner NK, et al (1999). UDPglucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics, 9, 341-9.
13. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
14. Naka N, Kawahara M, Okishio K, et al (2002). Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer, 37, 319-23.
15. Noda K, Nishiwaki Y, Kawahara M, et al(2002). Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small lung cancer. N Engl J Med, 346, 85-91.
16. Oshita F, Yamada K, Kato Y et al (2003). Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 52, 73-8.
17. Roth BJ, Johnson DH, Einhorn LH, et al (1992). Randomized study of cyclophosphamide,doxorubicin, and vincristine versus etoposide and cisplatin versus alternationof these two regimens in extensive small-cell lung cancer: a phase III trial ofthe Southeastern Cancer Study Group. J Clin Oncol, 10, 282-91.
18. Schmittel A, Fischer von Weikersthal L, Sebastian M, et al (2006). A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol, 17, 663-7.
19. Sundstrom S, Bremnes RM, Kaasa S, et al (2002). Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years followup. J Clin Oncol, 20, 4665-72.
20. Ueoka H, Kiura K, Tabata M, et al (1998). A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposid (PVP) versus sequential administration of VAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Cancer, 83, 283-90.
21. Von Pawel J, Schiller JH, Shepherd FA, et al (1999). Topotecan versus cyclophosphamide, doxorubicine, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol, 1, 658-67.
22. Zhang A, Xing Q, Qin S, et al (2007). Intra-ethnic differences in genetic variants of the GT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J, 7, 333-8.